Australia markets closed

Takeda Pharmaceutical Company Limited (TAK)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
13.02-0.05 (-0.38%)
As of 11:42AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 41.32B
Enterprise value 69.32B
Trailing P/E 35.97
Forward P/E 22.78
PEG ratio (5-yr expected) 3.20
Price/sales (ttm)1.53
Price/book (mrq)0.94
Enterprise value/revenue 0.02
Enterprise value/EBITDA 0.07

Trading information

Stock price history

Beta (5Y monthly) 0.54
52-week change 3-21.22%
S&P500 52-week change 321.08%
52-week high 317.11
52-week low 313.01
50-day moving average 314.10
200-day moving average 314.59

Share statistics

Avg vol (3-month) 31.84M
Avg vol (10-day) 31.64M
Shares outstanding 53.14B
Implied shares outstanding 63.16B
Float 81.55B
% held by insiders 10.00%
% held by institutions 12.68%
Shares short (15 Apr 2024) 45.97M
Short ratio (15 Apr 2024) 43.23
Short % of float (15 Apr 2024) 4N/A
Short % of shares outstanding (15 Apr 2024) 40.19%
Shares short (prior month 15 Mar 2024) 45.5M

Dividends & splits

Forward annual dividend rate 40.64
Forward annual dividend yield 44.88%
Trailing annual dividend rate 3184.00
Trailing annual dividend yield 31,407.80%
5-year average dividend yield 44.72
Payout ratio 4158.21%
Dividend date 311 Dec 2023
Ex-dividend date 428 Sept 2023
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in JPY.

Fiscal year

Fiscal year ends 31 Mar 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 4.28%
Operating margin (ttm)9.44%

Management effectiveness

Return on assets (ttm)2.61%
Return on equity (ttm)2.76%

Income statement

Revenue (ttm)4.17T
Revenue per share (ttm)1,335.47
Quarterly revenue growth (yoy)1.30%
Gross profit (ttm)N/A
EBITDA 1.21T
Net income avi to common (ttm)178.22B
Diluted EPS (ttm)0.36
Quarterly earnings growth (yoy)-11.30%

Balance sheet

Total cash (mrq)288.36B
Total cash per share (mrq)183.79
Total debt (mrq)5.21T
Total debt/equity (mrq)77.21%
Current ratio (mrq)1.06
Book value per share (mrq)4,297.21

Cash flow statement

Operating cash flow (ttm)731.45B
Levered free cash flow (ttm)-9.88B